DexCom, Inc. (NASDAQ:DXCM) Given Average Rating of “Moderate Buy” by Brokerages

DexCom, Inc. (NASDAQ:DXCM) has been given an average rating of “Moderate Buy” by the twenty-six ratings firms that are covering the stock, MarketBeat reports. One equities research analyst has rated the stock with a sell rating, three have issued a hold rating, nineteen have given a buy rating and three have given a strong buy rating to the company. The average 12-month target price among analysts that have covered the stock in the last year is $82.2083.

A number of research analysts have weighed in on the company. William Blair upgraded DexCom to a “strong-buy” rating in a report on Friday, May 15th. Barclays restated an “underweight” rating and issued a $64.00 price objective (down from $67.00) on shares of DexCom in a report on Monday, May 18th. Sanford C. Bernstein set a $77.00 price objective on DexCom in a report on Friday, May 1st. Raymond James Financial set a $81.00 price target on DexCom in a report on Friday, May 1st. Finally, Bank of America reduced their price target on DexCom from $100.00 to $80.00 and set a “buy” rating on the stock in a report on Monday, May 18th.

DexCom Trading Down 2.4%

Shares of DXCM stock opened at $70.26 on Friday. The stock’s fifty day moving average is $63.95 and its two-hundred day moving average is $66.27. The company has a debt-to-equity ratio of 0.42, a quick ratio of 1.64 and a current ratio of 1.95. The firm has a market capitalization of $27.11 billion, a P/E ratio of 30.03, a PEG ratio of 1.19 and a beta of 1.40. DexCom has a fifty-two week low of $54.11 and a fifty-two week high of $89.98.

DexCom (NASDAQ:DXCM) last announced its quarterly earnings data on Thursday, April 30th. The medical device company reported $0.56 earnings per share for the quarter, beating analysts’ consensus estimates of $0.47 by $0.09. The company had revenue of $1.19 billion for the quarter, compared to analyst estimates of $1.17 billion. DexCom had a return on equity of 33.33% and a net margin of 19.31%.The firm’s revenue for the quarter was up 15.0% on a year-over-year basis. During the same quarter last year, the firm posted $0.32 EPS. Research analysts expect that DexCom will post 2.57 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other DexCom news, Director Bridgette P. Heller sold 1,012 shares of DexCom stock in a transaction dated Tuesday, May 12th. The shares were sold at an average price of $60.01, for a total transaction of $60,730.12. Following the transaction, the director directly owned 25,007 shares of the company’s stock, valued at $1,500,670.07. The trade was a 3.89% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Michael Jon Brown sold 1,700 shares of DexCom stock in a transaction dated Wednesday, April 15th. The stock was sold at an average price of $63.04, for a total transaction of $107,168.00. Following the transaction, the executive vice president directly owned 111,204 shares in the company, valued at $7,010,300.16. This trade represents a 1.51% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 32,871 shares of company stock valued at $2,306,638 over the last ninety days. Company insiders own 0.28% of the company’s stock.

Hedge Funds Weigh In On DexCom

Institutional investors have recently bought and sold shares of the company. Trust Co. of Vermont increased its position in shares of DexCom by 14.8% during the 4th quarter. Trust Co. of Vermont now owns 1,122 shares of the medical device company’s stock worth $74,000 after purchasing an additional 145 shares during the last quarter. CVA Family Office LLC increased its position in shares of DexCom by 48.5% during the 4th quarter. CVA Family Office LLC now owns 450 shares of the medical device company’s stock worth $30,000 after purchasing an additional 147 shares during the last quarter. V Square Quantitative Management LLC increased its position in shares of DexCom by 1.8% during the 1st quarter. V Square Quantitative Management LLC now owns 9,618 shares of the medical device company’s stock worth $604,000 after purchasing an additional 172 shares during the last quarter. Essex Financial Services Inc. increased its position in shares of DexCom by 5.7% during the 1st quarter. Essex Financial Services Inc. now owns 3,256 shares of the medical device company’s stock worth $204,000 after purchasing an additional 175 shares during the last quarter. Finally, IFP Advisors Inc increased its position in shares of DexCom by 24.7% during the 3rd quarter. IFP Advisors Inc now owns 900 shares of the medical device company’s stock worth $61,000 after purchasing an additional 178 shares during the last quarter. 97.75% of the stock is owned by hedge funds and other institutional investors.

DexCom Company Profile

DexCom, Inc is a medical device company that develops, manufactures and distributes continuous glucose monitoring (CGM) systems for people with diabetes. Its products are designed to provide near real-time glucose readings, trend information and alerts to help patients and clinicians manage insulin dosing and reduce hypoglycemia and hyperglycemia. The company’s offerings combine wearable glucose sensors, wireless transmitters and software applications that deliver data to smartphones, dedicated receivers and cloud-based platforms for remote monitoring.

Founded in 1999 and headquartered in San Diego, California, DexCom has focused its business on advancing CGM technology and expanding clinical use beyond traditional insulin-dependent populations.